After repeated activation, however, these cells become anergic and switch to a cytokine profile that inhibits anti-tumor immune responses and favors tumor progression (i.e., a high ratio of IL-4 to IFN-γ) (Parekh et al. 2005). The gene discussed is IFNG; the disease is neoplasm.